Tonix Pharmaceuticals Holding (TNXP) Total Debt (2010 - 2024)

Tonix Pharmaceuticals Holding's (TNXP) quarterly Total Debt came in at $7.5 million in Q4 2024, down 15.98% year-on-year from $8.9 million in Q1 2024, and down 6.32% quarter-over-quarter from $8.0 million in Q3 2024.

Tonix Pharmaceuticals Holding (TNXP) Total Debt (2010 - 2024) Analysis & Trends

Tonix Pharmaceuticals Holding's Total Debt history runs 4 years deep, the most recent figure standing at $7.5 million for Q4 2024.

  • On a quarterly basis, Total Debt fell 15.98% year-over-year to $7.5 million in Q4 2024; TTM through Dec 2024 was $7.5 million, a 15.98% decrease from a year earlier, with the FY2024 full-year figure at $7.5 million, down 15.98% from the prior year.
  • Total Debt declined to $7.5 million in Q4 2024 per TNXP's latest filing, from $8.0 million in the prior quarter.
  • Across five years, Total Debt topped out at $9.0 million in Q1 2024 and bottomed at $7.5 million in Q4 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Oculis Holding AG 66,681.27 Bn 66,680.98 Bn - -
2 Nanobiotix 1,911.83 Bn 1,911.77 Bn - 110.96 Mn
3 Akari Therapeutics 959.56 Bn 959.56 Bn - -
4 BeOne Medicines 472.75 Bn 467.96 Bn 1.35 Bn 959.06 Mn
5 Vertex Pharmaceuticals 122.14 Bn 114.89 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 70.09 Bn 61.34 Bn 3.31 Bn 1.99 Bn
7 Belite Bio 62.34 Bn 62.34 Bn - -
8 Argenx Se 55.94 Bn 50.76 Bn 1.41 Bn -
9 Alnylam Pharmaceuticals 37.52 Bn 34.51 Bn 959.66 Mn -
10 Tonix Pharmaceuticals Holding 141.32 Mn 141.32 Mn 5.30 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2024 7.49 Mn
Sep 30, 2024 7.99 Mn
Jun 30, 2024 8.49 Mn
Mar 31, 2024 8.98 Mn
Dec 31, 2023 8.91 Mn
Dec 31, 2011 150,000.00
Sep 30, 2011 10,000.00
Jun 30, 2011 10,000.00
Dec 31, 2010 10,000.00